Unlike its counterpart, heart failure with reduced ejection fraction (HFrEF), which benefits from well-established pharmacological interventions such as beta-blockers, angiotensin-converting enzyme inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists, HFpEF remains a clinical enigma with fewer well-established treatment options, such as SGLT2 inhibitors and sacubitril/valsartan [2]. Here, SLC5A2 is linked to heart failure.